B-902

ブプレノルフィン 溶液

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

• 実験式（ヒル表記法）: C₂₉H₄₁NO₄
• CAS番号: 52485-79-7
• 分子量: 467.64
• EC Number: 200-659-6
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: certified reference material
• 形状: liquid
• 特徴: SNAP-N-SPIKE^®, SNAP-N-SHOOT^®
• 包装: ampule of 1 mL
• メーカー／製品名: Cerilliant^®
• drug control: Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)
• 濃度: 100 μg/mL in methanol
• テクニック: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• アプリケーション: forensics and toxicology
• フォーマット: single component solution
• 保管温度: 2-8°C
• SMILES記法: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56
• InChI: 1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
• InChI Key: RMRJXGBAOAMLHD-IHFGGWKQSA-N

詳細

詳細

Buprenex^®、Subutex^®、Suboxone^®の商品名で販売されているブプレノルフィンは、オピオイド依存症と中程度の急性疼痛の治療に使用されるアヘン薬です。この認定スパイキング溶液^®標準は、法医学分析、臨床毒物学、または医薬品研究におけるGC/MSまたはLC/MSアプリケーションに適しています。

アプリケーション

• Research on Addiction and Implementation Challenges: Buprenorphine solutions have been crucial in studies exploring how systemic barriers affect the implementation of addiction treatments during concurrent public health crises, offering insights valuable for policy and practice adjustments in healthcare systems (Sharp et al., 2023).


• Evaluating Patient-Important Measures in Opioid Use Disorder Treatments: Buprenorphine is used extensively to evaluate patient-important outcomes in medication-assisted treatment programs for opioid use disorders, aiding in the assessment of long-term recovery metrics and treatment efficacy (Reed et al., 2023).


• Web-Based Substance Use Epidemiology Research: Buprenorphine research solutions are instrumental in developing web-based ontologies for tracking and analyzing drug abuse trends, providing a foundational tool for public health surveillance and policy-making in substance abuse epidemiology (Lokala et al., 2022).


• Clinical Studies in Veterinary Medicine: Buprenorphine solutions are employed in veterinary medicine to assess the efficacy of transdermal applications for managing postoperative pain in animals, demonstrating its versatility and effectiveness across different biological systems (Clark et al., 2022).


• Pain Management in Geriatric Orthopedics: The use of transdermal buprenorphine for managing pain following femur fractures in elderly patients highlights its critical role in improving postoperative care and enhancing recovery outcomes in geriatric orthopedics (Davies et al., 2022).

法的情報

Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Suboxone is a registered trademark of RB Pharmaceuticals Limited

Subutex is a registered trademark of RB Pharmaceuticals Limited

安全性情報

• ピクトグラム: GHS02,GHS06,GHS08
• シグナルワード: Danger
• 危険有害性情報: H225,H301 + H311 + H331,H370
• 注意書き: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• 危険有害性の分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• ターゲットの組織: Eyes,Central nervous system
• 保管分類コード: 3 - Flammable liquids
• WGK: WGK 2
• 引火点(°F): 49.5 °F - closed cup
• 引火点(℃): 9.7 °C - closed cup